How to Get Tresiba in Hawaii: Prescriptions, Telehealth, and Pharmacies

What Is Tresiba and Why Do Hawaii Patients Request It?

Tresiba is a long-acting basal insulin with a half-life of approximately 25 hours and a duration of action exceeding 42 hours in most adults. [1] That extended profile gives it a flatter, more predictable pharmacodynamic curve than insulin glargine U-100, which matters for patients who struggle with nocturnal hypoglycemia or who cannot inject at the same hour every day. The FDA approved insulin degludec in September 2015 for adults with type 1 and type 2 diabetes, and a U-200 formulation followed shortly after for patients requiring larger daily volumes. [2]

Hawaii's patient population includes a high proportion of individuals of Native Hawaiian, Filipino, and Japanese ancestry, all groups that carry elevated type 2 diabetes prevalence compared with the national average. [3] The CDC's 2022 Behavioral Risk Factor Surveillance System data put Hawaii's diagnosed diabetes prevalence at roughly 9.5 percent among adults. [4] With that burden, demand for reliable basal insulin options is real, and Tresiba's dosing flexibility makes it a frequent request at both endocrinology and primary care offices across Oahu, Maui, Hawaii Island, and Kauai.

The DEVOTE trial (N=7,637) compared insulin degludec with insulin glargine U-100 in high-cardiovascular-risk type 2 diabetes patients over a median 2.0 years. Degludec produced a 40 percent lower rate of severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) while achieving non-inferior major adverse cardiovascular event rates. [5] That hypoglycemia advantage is clinically meaningful for older Hawaii patients who live alone or work physically demanding jobs.

The American Diabetes Association's 2024 Standards of Care state: "Compared to insulin glargine, insulin degludec is associated with significantly lower rates of nocturnal hypoglycemia in both type 1 and type 2 diabetes." [6] That guideline language gives prescribers a clear rationale when justifying the switch to payers.

Hawaii Telehealth Rules for Prescribing Tresiba

Telehealth prescribing of Tresiba is fully permitted in Hawaii. The Hawaii Telehealth Modernization Act and subsequent amendments allow a licensed prescriber to establish a valid patient-provider relationship via synchronous audio-video technology and write a non-controlled prescription in the same visit. Insulin degludec is not a controlled substance, so there are no DEA Schedule II restrictions limiting the encounter. [7]

The prescriber must hold an active Hawaii medical license and, for non-resident telehealth providers serving Hawaii patients, either a Hawaii telehealth registration or a full Hawaii license depending on the state's current reciprocity status. Patients should confirm their telehealth platform's prescriber holds Hawaii licensure before booking.

A telehealth visit for Tresiba typically runs 20 to 30 minutes. The provider will review blood glucose logs, current HbA1c, any prior insulin history, and relevant comorbidities. Prescriptions are sent electronically to the patient's preferred Hawaii pharmacy the same day in most cases. Mail-order delivery to a Hawaii address adds one to three business days. The full process from booking to first injection commonly takes three to seven days.

The Hawaii Medical Board has clarified that telehealth prescribers must document the clinical basis for each prescription, including the patient's diagnosis code (E10 for type 1, E11 for type 2), weight, current medications, and any known contraindications. [8] That documentation also supports prior authorization submissions if needed.

Which Labs Are Needed Before Starting Tresiba?

Labs are not universally mandated before the first Tresiba prescription, but every responsible prescriber will want recent values before selecting a starting dose. HbA1c is the single most useful number because it guides whether the patient is being initiated, switched, or up-titrated. A value drawn within the past three months is generally acceptable. [9]

A basic metabolic panel checks renal function, which affects both insulin sensitivity and hypoglycemia risk. Patients with an eGFR below 30 mL/min/1.73m² may need more conservative titration. [10] A fasting lipid panel and urine albumin-to-creatinine ratio round out a diabetes-focused lab panel by flagging cardiovascular and nephropathy risk that changes the overall management plan.

For patients switching from another basal insulin to Tresiba, the conversion table matters more than any single lab. Unit-for-unit conversion from insulin glargine U-100 or insulin detemir is standard, though many providers start Tresiba at 80 percent of the previous basal dose to reduce hypoglycemia risk during the transition period. [11] Patients switching from twice-daily insulin detemir should sum both doses and use that total as the starting Tresiba dose, again at 80 percent if hypoglycemia has been a prior issue.

Patients with type 1 diabetes also need a C-peptide and anti-GAD65 antibody panel if the diagnosis has never been confirmed biochemically, since misclassification (treating type 2 as type 1 or vice versa) produces dramatically different insulin dosing needs. [12]

Prior Authorization for Tresiba in Hawaii

Most Hawaii commercial insurers require prior authorization (PA) for Tresiba because it is a brand-name insulin without a currently FDA-approved interchangeable biosimilar at the same formulation. [13] Hawaii Medicaid (Med-QUEST) does not cover Tresiba at all for either type 1 or type 2 diabetes as of the most recent formulary review, meaning cash-pay or manufacturer assistance is the only path for Medicaid-enrolled patients.

A typical Hawaii insurer PA form asks for: the patient's diabetes type and diagnosis date, current HbA1c, a list of previously tried basal insulins and the reason each was discontinued, documentation of hypoglycemic episodes if switching from glargine or detemir on safety grounds, and the prescriber's NPI and Hawaii license number. The ADA's 2024 Standards of Care guidance on hypoglycemia specifically supports a switch to degludec when "recurrent clinically significant hypoglycemia" is documented. [14] That language directly satisfies the "tried-and-failed" criterion most insurers require.

Turnaround for PA decisions in Hawaii runs two to five business days for standard requests and 24 to 72 hours for urgent requests. Prescribers can submit urgent requests when a patient is being discharged from a hospital with a new insulin regimen or when a current insulin is on back-order.

How to Transfer a Tresiba Prescription to Hawaii

Transferring an existing Tresiba prescription to a Hawaii pharmacy is straightforward for retail prescriptions. Under Hawaii pharmacy law, a pharmacist at the receiving pharmacy contacts the dispensing pharmacy in the originating state, verifies the remaining refills, and enters the prescription into the Hawaii system. [15] Electronic prescriptions in the Surescripts network transfer automatically when the patient designates a new preferred pharmacy, provided the prescriber's license is valid and the prescription has refills remaining.

Mail-order prescriptions require the patient to contact the mail-order pharmacy's customer service line and update their shipping address. Most national mail-order pharmacies ship to all Hawaii ZIP codes. Standard shipping to Hawaii typically adds one to two business days compared with mainland delivery windows.

One caveat: if the originating prescription was written by a non-Hawaii-licensed provider and the patient is now residing in Hawaii permanently, that provider cannot continue prescribing. Hawaii law requires the prescriber of record to hold Hawaii licensure for ongoing prescribing to Hawaii residents. [16] In that scenario, the patient needs a new consultation with a Hawaii-licensed provider before refills can continue.

503A Compounding Pharmacies and Insulin Degludec in Hawaii

Hawaii-licensed 503A compounding pharmacies can prepare insulin degludec preparations for individual patients when a valid, patient-specific prescription exists. 503A pharmacies operate under Hawaii state pharmacy board oversight and must comply with USP Chapter 797 sterile compounding standards. [17] This pathway matters for patients who need a specific concentration, a preservative-free formulation, or a volume not available in the commercial Tresiba FlexTouch pen.

The FDA distinguishes 503A (patient-specific) from 503B (outsourcing facility, bulk production). Hawaii does not currently have a registered 503B outsourcing facility producing insulin degludec, so patients in Hawaii relying on compounded insulin degludec must go through a 503A pharmacy with an individual prescription. [18]

Compounded insulin degludec is not bioequivalent-tested against the branded product by regulatory standards, so most endocrinologists prefer the FDA-approved Tresiba when it is financially accessible. Manufacturer savings programs (the Novo Nordisk Patient Assistance Program and the $99/month My$99Insulin program) may make the branded product affordable enough to avoid compounding entirely. [19]

Finding a Prescriber in Hawaii for Tresiba

Hawaii has roughly 85 board-certified endocrinologists statewide, with concentration on Oahu (Honolulu) and limited coverage on neighbor islands. [20] The American Association of Clinical Endocrinology's member directory lists Hawaii providers, and the Endocrine Society's Find-a-Patient-Care-Team tool covers both in-person and telehealth-accepting specialists. [21]

Primary care physicians and nurse practitioners write the majority of basal insulin prescriptions in Hawaii, especially on Maui, Hawaii Island, and Kauai where specialist access is limited. Hawaii Advanced Practice Registered Nurses (APRNs) operate under full practice authority, meaning they do not require physician collaboration agreements to prescribe Tresiba independently. [22] Physician assistants in Hawaii prescribe under delegated authority from a supervising physician, but in practice that supervision can be remote and asynchronous.

Telehealth platforms that are licensed in Hawaii and can prescribe Tresiba include endocrine-focused services that operate nationwide. Patients should verify three things before scheduling: (1) the provider holds an active Hawaii license, (2) the platform sends electronic prescriptions to Hawaii pharmacies directly, and (3) the visit includes a clinical review of glucose data rather than a purely administrative refill encounter.

The Endocrine Society's 2022 clinical practice guideline on insulin therapy states: "Insulin degludec may be preferred over insulin glargine U-100 in patients with type 2 diabetes at high risk for hypoglycemia, particularly those with impaired hypoglycemia awareness or advanced age." [23]

Pharmacy Access and Pricing in Hawaii

Major retail chains operating in Hawaii that typically stock Tresiba include CVS (multiple Oahu locations), Longs Drugs (a CVS subsidiary with broad Hawaii Island presence), Walgreens (Oahu and Maui), Costco Pharmacy (Honolulu), and Walmart Pharmacy (Oahu). Safeway and Times Supermarket pharmacies also carry it, though neighbor island locations may require a 24 to 48 hour order lead time. [24]

Cash-pay pricing for Tresiba FlexTouch 100 units/mL (5 pens, 300 units each) runs approximately $350 to $450 per box at Hawaii retail pharmacies without insurance or assistance programs. The Novo Nordisk My$99Insulin program caps monthly insulin costs at $99 for eligible patients regardless of the number of packs needed, with no income limit for that specific program. [25] GoodRx and similar discount programs reduce cash pricing at some Hawaii pharmacies to roughly $280 to $320 per box, though these discount prices cannot be combined with insurance.

For patients with private insurance, a formulary tier 2 or tier 3 placement typically produces a $45 to $90 copay per box after PA approval. Hawaii's Act 216 (2019) capped insulin copays at $100 per 30-day supply for state-regulated health plans, providing meaningful protection for insured Hawaii residents. [26]

Titrating Tresiba After Starting in Hawaii

Once the prescription is filled and the first dose is injected, patients need a structured titration plan. The most commonly cited protocol in the DEVOTE trial used a treat-to-target fasting glucose goal of 80 to 90 mg/dL (4.4 to 5.0 mmol/L). [5] A simpler community-care version, sometimes called the 3-0-3 rule, adjusts the Tresiba dose by 3 units every three days based on the average fasting glucose from the preceding three mornings. [27]

Patients should check fasting blood glucose every morning for the first four weeks and share logs with their Hawaii provider at a follow-up visit scheduled 30 days after initiation. HbA1c should be repeated at 90 days to assess population-level glycemic response. If fasting glucose targets are not met by week 12 despite titration, the prescriber should evaluate mealtime insulin need, GLP-1 receptor agonist addition, or adherence barriers before escalating the basal dose further. [28]

Hypoglycemia below 70 mg/dL requires dose reduction and same-day contact with the prescriber. Severe hypoglycemia requiring assistance from another person requires an emergency contact call and provider notification before the next injection. The DEVOTE trial documented a severe hypoglycemia rate of 0.93 episodes per patient-year with degludec versus 1.52 with glargine. [5] That difference translates meaningfully in Hawaii, where some patients travel long distances to emergency departments, adding risk to every severe episode.

Patient Assistance and Financial Resources

Novo Nordisk's Patient Assistance Program (PAP) provides free Tresiba to patients who meet income criteria, generally at or below 400 percent of the federal poverty level with no private insurance covering insulin. [29] Hawaii patients can apply online or through a Hawaii-licensed prescriber who completes the provider portion of the application form.

The Juvenile Diabetes Research Foundation (JDRF) Hawaii chapter and the American Diabetes Association's Hawaii affiliate both maintain lists of local financial assistance resources. [30] Some Hawaii federally qualified health centers (FQHCs), including those operated by Kokua Kalihi Valley and Waimanalo Health Center, provide sliding-scale pharmacy services that include basal insulin for uninsured patients. [31]

Patients enrolled in Hawaii's QUEST Integration Medicaid program who do not have Tresiba coverage should ask their prescriber about insulin glargine U-300 (Toujeo), which does appear on some QUEST formularies and shares several pharmacodynamic advantages with degludec, including reduced nocturnal hypoglycemia compared with U-100 glargine. [32] That substitution may be preferable to paying full cash price for Tresiba.

Patients who qualify for Medicare Part D should review plan formularies during the annual open enrollment window (October 15 to December 7 each year), since some Hawaii Part D plans place Tresiba on tier 3 with PA while others exclude it entirely and require a formulary exception request. [33]